每經AI快訊，華海藥業（SH 600521，收盤價：22.71元）8月25日晚間發布公(gong)告稱(cheng)，為滿(man)足公(gong)司(si)(si)下屬(shu)全資子(zi)公(gong)司(si)(si)華海建誠在(zai)業務發展及(ji)建設過程(cheng)中的資金(jin)需求，公(gong)司(si)(si)于(yu)2025年(nian)8月25日召開第(di)九屆董事會第(di)四(si)次臨時會議，審議通過了《關于(yu)公(gong)司(si)(si)為下屬(shu)子(zi)公(gong)司(si)(si)提供擔保議案》，同意公(gong)司(si)(si)為下屬(shu)子(zi)公(gong)司(si)(si)華海建誠向銀(yin)行申請(qing)授信額(e)度提供合(he)計不超過2.05億元（最終以實(shi)際(ji)發生額(e)為準）的信用擔保。

截至本公(gong)(gong)(gong)(gong)(gong)告披露日，公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及下屬(shu)子(zi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)對(dui)外(wai)擔保總(zong)額(e)約(yue)為35.72億(yi)元占公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)最(zui)近一期經(jing)審計(ji)歸屬(shu)于上(shang)市(shi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東(dong)(dong)所有者權(quan)(quan)益(yi)的40.15%，均(jun)為公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)對(dui)下屬(shu)子(zi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、參股公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)提供的擔保。其中公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)對(dui)子(zi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)的擔保總(zong)額(e)約(yue)為31.05億(yi)元，占公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)最(zui)近一期經(jing)審計(ji)歸屬(shu)于上(shang)市(shi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東(dong)(dong)所有者權(quan)(quan)益(yi)的34.89%；公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)對(dui)參股公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)的擔保總(zong)額(e)約(yue)為2.63億(yi)元，最(zui)近一期經(jing)審計(ji)歸屬(shu)于上(shang)市(shi)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東(dong)(dong)所有者權(quan)(quan)益(yi)的2.95%。

2024年1至(zhi)12月(yue)份，華海藥業的營業收入(ru)構成為：成品藥銷售占(zhan)比(bi)(bi)(bi)60.32%，原材料及中間體(ti)銷售占(zhan)比(bi)(bi)(bi)38.19%，技術(shu)服務占(zhan)比(bi)(bi)(bi)0.66%，其他業務占(zhan)比(bi)(bi)(bi)0.55%，其他行(xing)業占(zhan)比(bi)(bi)(bi)0.28%。

截至發稿，華海(hai)藥(yao)業市值為340億元。

每(mei)經頭(tou)條（nbdtoutiao）——

（記者 王曉波）

免責聲明(ming)：本文內容(rong)與數據僅供參(can)考，不構成(cheng)投資建議，使用前請核實。據此操(cao)作，風(feng)險自(zi)擔(dan)。